PharVision Advisers’s Bankunited BKU Stock Holding History

PharVision Advisers’s Portfolio BKU Stock Details BKU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,454	Closed	-$243K	–	161
2025 Q4	$243K	Sell	5,454 -226	-4%	-$9.36K	0.12%	412
2025 Q3	$217K	Buy	+5,680	New	+$215K	0.12%	446
2025 Q2	–	Sell	-10,912	Closed	-$376K	–	285
2025 Q1	$376K	Buy	+10,912	New	+$411K	0.52%	51

Other funds holding BKU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HAM

HoldCo Asset Management Fort Lauderdale, Florida $1.56B AUM 45.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PharVision Advisers's BKU Position: Q1 2026 in Review

PharVision Advisers sold out of Bankunited (BKU) in Q1 2026, closing a stake of 5,454 shares — an estimated $243K sold.

PharVision Advisers first reported a position in BKU in Q1 2025 and held it in 3 quarters. The position peaked at $376K in Q1 2025. 326 funds tracked by Wall St. Rank hold BKU as of Q1 2026.

PharVision Advisers reported no remaining Bankunited position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 5,454 Bankunited shares in Q1 2026, an estimated $243K.
PharVision Advisers first reported a position in Bankunited in Q1 2025 and held it in 3 quarters.
PharVision Advisers's Bankunited position peaked at $376K in Q1 2025.
326 funds tracked by Wall St. Rank held Bankunited as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.